IRCT138902113846N1
Completed
未知
Intravitreal bevacizumab(Avastin) for macular edema secondary to uveitis: 1 year results of a prospective pilot study
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Macular edema secondary to uveitis.
- Sponsor
- Shiraz University of Medical Sciences
- Enrollment
- 30
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •In a prospective clinical trial consecutive 30 patients with uveitis and CME will be enroll in the study. None of the patients will have a systemic or an ocular disease other than the one causing uveitis.
- •Patients with history of other diseases causing macular edema (such as diabetes mellitus and retinal vein occlusions) will be excluded from the study. All of the patients should have decreased vision due to Cystoid Macular Edema (CME),
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Intravitreal bevacizumab injection for intraocular neovascularization in childreRetinopathy of prematurityJPRN-UMIN000014316Kansai Medical University15
Not yet recruiting
Not Applicable
Intravitreal Bevaxizumab injection for intraocular neovasculalization in childreretinopathy of prematurityJPRN-UMIN000007465Tokushima university hospital10
Active, not recruiting
Not Applicable
Intravitreal Bevacizumab (Avastin) for neovascular age-related macular degeneration - NDViasual acuity lossMedDRA version: 9.1Level: SOCClassification code 10015919Term: Eye disordersEUCTR2006-004320-36-ITAZIENDA OSPEDALIERA SENESE
Active, not recruiting
Not Applicable
Intravitreal Bevacizumab Avastin, Roche, United Kingdom for exudative maculopathies - Intravitreal bevacizumabEUCTR2005-006182-14-ITIVERSITA DEGLI STUDI DI UDINE30
Recruiting
Not Applicable
Treatment with bevacizumab for ocular vascular lesionsOcular vascular lesionsJPRN-UMIN000020916Keio University, School of Medicine1,000